双靶向NET形成与凝血改善实验性脓毒症生存及器官保护
该研究在盲肠结扎穿孔诱导的C57BL/6J小鼠脓毒症模型中,造模后给予Cl-amidine(50 mg/kg腹腔注射)和/或肝素(1,000 U/kg静脉注射)治疗,评估7天生存率、循环NET标志物、炎症细胞因子、凝血参数及肺、肝、肾组织病理损伤。结果显示,联合治疗较未治疗脓毒症小鼠显著改善7天生存,而Cl-amidine单药虽显著降低NET标志物却未带来生存获益;肝素单药对NET标志物无统计学显著影响;联合治疗进一步降低髓过氧化物酶水平,且肺、肝、肾损伤在联合组减轻最明显。联合方案对部分炎症和凝血指标的改善与更有效的单药治疗相当,未观察到统计学证实的药理协同作用。作者认为联合干预在单药基础上产生附加保护效应,但组织学保护不能由全身细胞因子进一步抑制或整体凝血参数变化解释,机制尚不完全明确;临床转化前需进一步临床前研究评估出血风险、最佳给药策略和机制通路。
要点
- 小鼠脓毒症模型中,Cl-amidine(50 mg/kg腹腔注射)联合肝素(1,000 U/kg静脉注射)较未治疗显著改善7天生存。
- Cl-amidine单药虽显著降低NET标志物,但未带来生存获益;肝素单药对NET标志物无统计学显著影响。
- 联合治疗进一步降低髓过氧化物酶水平,肺、肝、肾组织病理损伤在联合组减轻最明显。
- 联合方案对部分炎症和凝血指标的改善与更有效的单药治疗相当,未观察到统计学证实的药理协同作用。
- 组织学保护不能由全身细胞因子进一步抑制或整体凝血参数变化解释,机制尚不完全明确;临床转化前需进一步临床前研究评估出血风险、最佳给药策略和机制通路。
适用人群与场景
- C57BL/6J小鼠,采用盲肠结扎穿孔模型诱导脓毒症,造模后接受治疗。
处置流程与药物剂量
- 造模后给予Cl-amidine 50 mg/kg腹腔注射和/或肝素1,000 U/kg静脉注射。
研究设计与关键结果
- 研究类型为动物实验(小鼠盲肠结扎穿孔脓毒症模型),评估造模后Cl-amidine(50 mg/kg腹腔注射)和/或肝素(1,000 U/kg静脉注射)治疗对7天生存、循环NET相关标志物(瓜氨酸化组蛋白H3和髓过氧化物酶)、炎症细胞因子、凝血参数及肺、肝、肾组织病理损伤的影响。
- 联合治疗较未治疗脓毒症小鼠显著改善7天生存;Cl-amidine单药虽显著降低NET标志物但未带来生存获益。
- Cl-amidine显著降低NET形成,肝素单药对NET标志物无统计学显著影响;联合治疗进一步降低髓过氧化物酶水平。
- 肺、肝、肾组织病理损伤在联合组较任一单药组减轻最明显。
- 联合方案对部分炎症和凝血指标的改善与更有效的单药治疗相当,未观察到统计学证实的药理协同作用。
证据类型、等级与局限
- 证据类型:动物实验(小鼠脓毒症模型)。
- 局限:组织学保护不能由全身细胞因子进一步抑制或整体凝血参数变化解释,机制尚不完全明确;临床转化前需进一步临床前研究评估出血风险、最佳给药策略和机制通路。
对床旁实践的改变
- 作者认为联合干预在单药基础上产生附加保护效应,但该结论来自小鼠实验性脓毒症模型,作者指出临床转化前需进一步临床前研究评估出血风险、最佳给药策略和机制通路。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Sepsis is a life-threatening critical illness characterized by dysregulated host responses, in which excessive neutrophil extracellular trap (NET) formation and sepsis-associated coagulopathy play central roles in organ dysfunction and mortality. Targeting a single pathological pathway has shown limited clinical benefit. Cl-amidine, a peptidylarginine deiminase 4 inhibitor, suppresses NET formation, whereas heparin is widely used in critically ill patients to modulate coagulation and neutralize histone-mediated cytotoxicity. Whether simultaneous targeting of NET-driven inflammation and coagulation dysregulation provides enhanced protection in sepsis remains unclear.
METHODS: Sepsis was induced in C57BL/6J mice using the cecal ligation and puncture model. Mice received postinsult treatment with Cl-amidine (50 mg/kg, intraperitoneally) and/or heparin (1,000 U/kg, intravenously). Seven-day survival was assessed. Circulating NET-related markers (citrullinated histone H3 and myeloperoxidase), inflammatory cytokines, coagulation parameters, and histopathological injury of the lung, liver, and kidney were evaluated.
RESULTS: Combined treatment with Cl-amidine and heparin significantly improved 7-day survival compared with untreated septic mice, whereas Cl-amidine monotherapy did not confer a survival benefit despite significantly reducing NET markers. Cl-amidine significantly reduced NET formation, whereas heparin alone did not show a statistically significant effect on NET markers. Combined treatment further enhanced the reduction of myeloperoxidase levels. Histopathological analysis demonstrated that pulmonary, hepatic, and renal injury were most markedly attenuated in the combination group compared with either monotherapy. Although inflammatory and coagulation parameters were generally improved following treatment, the effects of the combined regimen were comparable to those of the more effective monotherapy for several markers, and no statistically confirmed pharmacological synergy was observed.
CONCLUSIONS: Combined administration of Cl-amidine and heparin provides a meaningful survival benefit and attenuates multiorgan injury in experimental sepsis. Although no statistically confirmed pharmacological synergy was observed across all parameters, the combined intervention exerted additive protective effects beyond single-agent treatment. Importantly, the additional histological protection could not be explained by further suppression of systemic cytokines or by changes in global coagulation parameters, and the underlying mechanisms therefore remain incompletely defined. Further preclinical studies addressing bleeding risk, optimal dosing strategies, and mechanistic pathways are warranted before clinical translation.
参考来源
- Zhang X, Wu J, Guo S, et al. Dual Targeting of Net Formation and Coagulation Improves Survival and Organ Protection in Experimental Sepsis. Shock. 2026. PMID: 41894635. doi:10.1097/SHK.0000000000002824
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。